NovaBay Pharmaceuticals, a developer of patented Aganocide compounds, has unveiled its NeutroPhase.

NeutroPhase consists of pure, isotonic stable hypochlorous acid solution to treat chronic non-healing wounds, such as pressure, venous stasis and diabetic ulcers.

Hypochlorous acid is an anti-biofilm, broad-spectrum, antimicrobial agent which is similar to agent produced by white blood cells to defend against bacteria and is safe, well-tolerated in human tissues.

NeutroPhase is packaged in a convenient glass container which will insure its long-term shelf stability.

NeutroPhase has received two 510(k) clearances from the US Food and Drug Administration (FDA) as a wound cleanser.